Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Legend Capital Closes $156 Million Phase II for RMB Healthcare Fund

publication date: May 21, 2018

Legend Capital, the controlling shareholder of Lenovo Group, completed a $156 million capital raise for its RMB China healthcare fund. The fund will invest in innovative medicines, precise treatments, medical devices, diagnostic technologies, medical services and genetic technologies. This is the second phase of the RMB healthcare fund, which closed its first fundraising last year. The second phase will expand its investing strategy across early-stage to later-stage investments. The firm also plans to close a US dollar healthcare fund in Q3 of this year. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital